A clinical study involving TNFerade biologic (adenovector delivering tumor necrosis factor-alpha (TNF-α) to tumor cells) in locally advanced pancreatic cancer patients confirmed its safety but failed to demonstrate an extension in survival [61]. Here, TNF is linked to pancreatic neoplasm.